Terms: = Lymphoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
4079 results:
1. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
[TBL] [Abstract] [Full Text] [Related]
2. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
[TBL] [Abstract] [Full Text] [Related]
3. p53-Armed Oncolytic Virotherapy Improves Radiosensitivity in Soft-Tissue Sarcoma by Suppressing BCL-xL Expression.
Komatsubara T; Tazawa H; Hasei J; Omori T; Sugiu K; Mochizuki Y; Demiya K; Yoshida A; Fujiwara T; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Acta Med Okayama; 2024 Apr; 78(2):151-161. PubMed ID: 38688833
[TBL] [Abstract] [Full Text] [Related]
4. The tp53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E; Sandoz J; Romero G; Zadra I; Urgel-Solas J; Borredat P; Kourtis S; Ortet L; Martínez CM; Weghorn D; Sdelci S; Janic A
J Exp Clin Cancer Res; 2024 Apr; 43(1):127. PubMed ID: 38685100
[TBL] [Abstract] [Full Text] [Related]
5. Cytogenetic abnormalities and tp53 and RAS gene profiles of childhood acute lymphoblastic leukemia in Morocco.
Skhoun H; El Fessikh M; El Alaoui Al Abdallaoui M; Khattab M; Belkhayat A; Chebihi ZT; Hassani A; Abilkassem R; Agadr A; Dakka N; El Baghdadi J
Arch Pediatr; 2024 May; 31(4):238-244. PubMed ID: 38679547
[TBL] [Abstract] [Full Text] [Related]
6. Putting the STING back into BH3-mimetic drugs for tp53-mutant blood cancers.
Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
[TBL] [Abstract] [Full Text] [Related]
7. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract] [Full Text] [Related]
8. Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma, Version 2.2024.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Cortese M; Cripe L; Davis RS; Eradat H; Fakhri B; Fletcher CD; Gaballa S; Hamid MS; Hill B; Kaesberg P; Kahl B; Kamdar M; Kipps TJ; Ma S; Mosse C; Nakhoda S; Parikh S; Schorr A; Schuster S; Seshadri M; Siddiqi T; Stephens DM; Thompson M; Ujjani C; Valdez R; Wagner-Johnston N; Woyach JA; Sundar H; Dwyer M
J Natl Compr Canc Netw; 2024 Apr; 22(3):175-204. PubMed ID: 38626800
[TBL] [Abstract] [Full Text] [Related]
9. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like lymphomas in mice.
Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
[TBL] [Abstract] [Full Text] [Related]
10. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract] [Full Text] [Related]
11. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract] [Full Text] [Related]
12. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
13. Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.
Chen Z; Huang H; Hong H; Huang H; Weng H; Yu L; Xiao J; Wang Z; Fang X; Yao Y; Yue JX; Lin T
Genome Med; 2024 Apr; 16(1):48. PubMed ID: 38566223
[TBL] [Abstract] [Full Text] [Related]
14. Induction of breast cancer cell apoptosis by novel thiouracil-fused heterocyclic compounds through boosting of Bax/Bcl-2 ratio and DFT study.
Mansour E; Abd-Rabou AA; El-Atawy MA; Ahmed HA; El-Farargy AF; Abd El-Mawgoud HK
Bioorg Chem; 2024 May; 146():107292. PubMed ID: 38555798
[TBL] [Abstract] [Full Text] [Related]
15. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological and molecular genetic alterations in monomorphic-epitheliotropic intestinal T-cell lymphoma of the small intestine.
Zhou B; Guo M; Li X; Duan T; Peng L; Hao H
Eur J Med Res; 2024 Mar; 29(1):191. PubMed ID: 38520011
[TBL] [Abstract] [Full Text] [Related]
17. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphoma.
Cho SF; Yeh TJ; Wang HC; Du JS; Gau YC; Lin YY; Chuang TM; Liu YC; Hsiao HH; Moi SH
Sci Rep; 2024 Mar; 14(1):6161. PubMed ID: 38485750
[TBL] [Abstract] [Full Text] [Related]
19. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract] [Full Text] [Related]
20. tp53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
[TBL] [Abstract] [Full Text] [Related]
[Next]
